Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis, Published online: 06 June 2018; doi:10.1038/s41391-018-0055-8Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 6, 2018 Category: Urology & Nephrology Authors: Pui San Tan Pedro Aguiar Jr. Benjamin Haaland Gilberto Lopes Source Type: research

Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study
Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study, Published online: 04 June 2018; doi:10.1038/s41391-018-0054-9Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 4, 2018 Category: Urology & Nephrology Authors: De Nunzio Cosimo Brassetti Aldo Simone Giuseppe Lombardo Riccardo Mastroianni Riccardo Collura Devis Muto Giovanni Gallucci Michele Tubaro Andrea Source Type: research

The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP)
The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP), Published online: 01 June 2018; doi:10.1038/s41391-018-0051-zThe association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP) (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Joseph Brito III Jorge Pereira Daniel M. Moreira Gyan Pareek Christopher Tucci Ruiting Guo Zheng Zhang Ali Amin Anthony Mega Joseph Renzulli II Dragan Golijanin Boris Gershman Source Type: research

Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study
Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study, Published online: 01 June 2018; doi:10.1038/s41391-018-0047-8Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Wei-Ming Li Nelly Pasaribu Su-Shin Lee Wen-Chan Tsai Chia-Yang Li Gau-Tyan Lin Hung-Yi Chuang Yi-Ching Tung Hung-Pin Tu Source Type: research

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients
Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients, Published online: 01 June 2018; doi:10.1038/s41391-018-0043-zPrognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Manish Kohli Jian Li Meijun Du David W Hillman Scott M. Dehm Winston Tan Rachel Carlson Michael B. Campion Liguo Wang Liewei Wang Huijuan Zhang Peng Zhang Deepak Kilari Chiang-Ching Huang Liang Wang Source Type: research

Reply to the letter by Demark-Wahnefried et al.
Reply to the letter by Demark-Wahnefried et al., Published online: 01 June 2018; doi:10.1038/s41391-018-0050-0Reply to the letter by Demark-Wahnefried et al. (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: William J. Aronson Susanne M. Henning Source Type: research

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?, Published online: 01 June 2018; doi:10.1038/s41391-018-0049-6Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Landon C. Brown Guru Sonpavde Andrew J. Armstrong Source Type: research

Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’
Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’, Published online: 01 June 2018; doi:10.1038/s41391-018-0052-yReply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’ (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Behfar Ehdaie Sigrid Carlsson Source Type: research

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer
Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer, Published online: 01 June 2018; doi:10.1038/s41391-018-0046-9Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: Karthik V. Giridhar Cristobal Sanhueza David W Hillman Hassan Alkhateeb Rachel Carlson Winston Tan Brian A. Costello Fernando Quevedo Lance Pagliaro Manish Kohli Source Type: research

68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology
68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology, Published online: 01 June 2018; doi:10.1038/s41391-018-0048-768Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - June 1, 2018 Category: Urology & Nephrology Authors: I. Berger C. Annabattula J. Lewis D. V. Shetty J. Kam F. Maclean M. Arianayagam B. Canagasingham R. Ferguson M. Khadra R. Ko M. Winter H. Loh C. Varol Source Type: research

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study, Published online: 23 May 2018; doi:10.1038/s41391-018-0044-yPSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 23, 2018 Category: Urology & Nephrology Authors: Devin N. Patel Tom Feng Ross M. Simon Lauren E. Howard Adriana C. Vidal Daniel M. Moreira Ramiro Castro-Santamaria Claus Roehrborn Gerald L. Andriole Stephen J. Freedland Source Type: research

The microbiome in prostate inflammation and prostate cancer
The microbiome in prostate inflammation and prostate cancer, Published online: 23 May 2018; doi:10.1038/s41391-018-0041-1The microbiome in prostate inflammation and prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 23, 2018 Category: Urology & Nephrology Authors: Corey M. Porter Eva Shrestha Lauren B. Peiffer Karen S. Sfanos Source Type: research

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer, Published online: 23 May 2018; doi:10.1038/s41391-018-0045-xSerum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 23, 2018 Category: Urology & Nephrology Authors: Emma H. Allott Elizabeth M. Masko Alexis R. Freedland Everardo Macias Kristine Pelton Keith R. Solomon Elahe A. Mostaghel George V. Thomas Salvatore V. Pizzo Michael R. Freeman Stephen J. Freedland Source Type: research

Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement
Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statementWhich technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement, Published online: 09 May 2018; doi:10.1038/s41391-018-0042-0Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 9, 2018 Category: Urology & Nephrology Authors: Roman Ganzer Vinodh Kumar Adithyaa Arthanareeswaran Hashim U. Ahmed Andrea Cestari Pascal Rischmann Georg Salomon Dogu Teber Evangelos Liatsikos Jens-Uwe Stolzenburg Eric Barret Source Type: research

Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study
Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study, Published online: 02 May 2018; doi:10.1038/s41391-018-0036-yDevelopment of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 2, 2018 Category: Urology & Nephrology Authors: Huah Shin Ng Bogda Koczwara David Roder Agnes Vitry Source Type: research

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer, Published online: 27 April 2018; doi:10.1038/s41391-018-0037-xChanges in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 27, 2018 Category: Urology & Nephrology Authors: M. M. Cherrier D. J. Cross C. S. Higano S. Minoshima Source Type: research

Does the association of prostate cancer with night-shift work differ according to rotating vs. fixed schedule? A systematic review and meta-analysis
Does the association of prostate cancer with night-shift work differ according to rotating vs. fixed schedule? A systematic review and meta-analysis, Published online: 27 April 2018; doi:10.1038/s41391-018-0040-2Does the association of prostate cancer with night-shift work differ according to rotating vs. fixed schedule? A systematic review and meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 27, 2018 Category: Urology & Nephrology Authors: Jennifer Mancio C átia Leal Marta Ferreira Pedro Norton Nuno Lunet Source Type: research

Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”
Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”, Published online: 24 April 2018; doi:10.1038/s41391-018-0038-9Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy” (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 24, 2018 Category: Urology & Nephrology Authors: W. Demark-Wahnefried S. Rais-Bahrami R. A. Desmond J. B. Gordetsky M. Azrad A. D. Frug é E. S. Yang L. A. Norian W. E. Grizzle Source Type: research

Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction
Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction, Published online: 24 April 2018; doi:10.1038/s41391-018-0039-8Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 24, 2018 Category: Urology & Nephrology Authors: M. Samarinas M. Gacci A. de la Taille S. Gravas Source Type: research

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer
Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer, Published online: 20 March 2018; doi:10.1038/s41391-018-0035-zCombining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - March 20, 2018 Category: Urology & Nephrology Authors: Benjamin Benzon Stephanie A. Glavaris Brian W. Simons Robert M. Hughes Kamyar Ghabili Patrick Mullane Rebecca Miller Katriana Nugent Brian Shinder Jeffrey Tosoian Ephraim J. Fuchs Phuoc T. Tran Paula J. Hurley Milena Vuica-Ross Edward M. Schaeffer Charles Source Type: research

Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial
Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial, Published online: 08 March 2018; doi:10.1038/s41391-018-0034-0Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - March 8, 2018 Category: Urology & Nephrology Authors: Alessandro Magli Eugenia Moretti Annarita Tullio Gianluca Giannarini Fabrizio Tonetto Mauro Urpis Margherita Crespi Claudio Foti Agnese Prisco Margherita Polsinelli Gioacchino De Giorgi Giulia Bravo Paolo Scalchi Marco Trov ò Source Type: research

Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis
Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis, Published online: 27 February 2018; doi:10.1038/s41391-018-0032-2Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - February 27, 2018 Category: Urology & Nephrology Authors: Jurate Noreikaite Patrick Jones John Fitzpatrick Ramachandran Amitharaj Amelia Pietropaolo Nikhil Vasdev David Chadwick Bhaskar K. Somani Bhavan Prasad Rai Source Type: research

Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram, Published online: 27 February 2018; doi:10.1038/s41391-018-0033-1Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - February 27, 2018 Category: Urology & Nephrology Authors: Raisa S. Pompe Marco Bandini Felix Preisser Michele Marchioni Emanuele Zaffuto Zhe Tian Georg Salomon Thorsten Schlomm Hartwig Huland Markus Graefen Derya Tilki Shahrokh F. Shariat Pierre I. Karakiewicz Source Type: research

Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5%
Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is
Source: Prostate Cancer and Prostatic Diseases - February 22, 2018 Category: Urology & Nephrology Authors: Francesco Porpiglia Matteo Manfredi Fabrizio Mele Riccardo Bertolo Enrico Bollito Dario Gned Agostino De Pascale Filippo Russo Roberto Passera Cristian Fiori Stefano De Luca Source Type: research

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based studyTumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study, Published online: 16 January 2018; doi:10.1038/s41391-017-0006-9Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 16, 2018 Category: Urology & Nephrology Authors: Raisa S. Pompe Ariane Smith Marco Bandini Michele Marchioni Tristan Martel Felix Preisser Sami-Ramzi Leyh-Bannurah Jonas Schiffmann Fred Saad Hartwig Huland Markus Graefen Shahrokh F. Shariat Derya Tilki Pierre I. Karakiewicz Source Type: research

Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells
Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cellsOverexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells, Published online: 16 January 2018; doi:10.1038/s41391-017-0016-7Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 16, 2018 Category: Urology & Nephrology Authors: Naseruddin H öti Shuang Yang Yingwei Hu Punit Shah Michael C. Haffner Hui Zhang Source Type: research

Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysis
Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysisProcessed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysis, Published online: 09 January 2018; doi:10.1038/s41391-017-0005-xProcessed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 9, 2018 Category: Urology & Nephrology Authors: Joe L. Rowles III Katherine M. Ranard Catherine C. Applegate Sookyoung Jeon Ruopeng An John W. Erdman Jr Source Type: research

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer, Published online: 04 January 2018; doi:10.1038/s41391-017-0027-4p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 4, 2018 Category: Urology & Nephrology Authors: Benjamin L. Maughan Liana B. Guedes Kenneth Boucher Gaurav Rajoria Zach Liu Szczepan Klimek Roberto Zoino Emmanuel S. Antonarakis Tamara L. Lotan Source Type: research

Current approaches to incorporation of radium-223 in clinical practice
Current approaches to incorporation of radium-223 in clinical practice, Published online: 03 January 2018; doi:10.1038/s41391-017-0020-yCurrent approaches to incorporation of radium-223 in clinical practice (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 3, 2018 Category: Urology & Nephrology Authors: Chris Parker Axel Heidenreich Sten Nilsson Neal Shore Source Type: research

Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases
Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases, Published online: 03 January 2018; doi:10.1038/s41391-017-0029-2Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 3, 2018 Category: Urology & Nephrology Authors: L. M. FitzGerald S. Zhao A. Leonardson M. S. Geybels S. Kolb D. W. Lin J. L. Wright R. Eeles Z. Kote-Jarai K. Govindasami G. G. Giles M. C. Southey J. Schleutker T. L. Tammela C. Sipeky K. L. Penney M. J. Stampfer H. Gronberg F. Wiklund P. Stattin J. Hugo Source Type: research

Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis
Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis, Published online: 02 January 2018; doi:10.1038/s41391-017-0028-3Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 2, 2018 Category: Urology & Nephrology Authors: Mohannad A. Awad Thomas W. Gaither E. Charles Osterberg Gregory P. Murphy Nima Baradaran Benjamin N. Breyer Source Type: research

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study, Published online: 27 December 2017; doi:10.1038/s41391-017-0030-9Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 27, 2017 Category: Urology & Nephrology Authors: Juzar Jamnagerwalla Lauren E. Howard Emma H. Allott Adriana C. Vidal Daniel M. Moreira Ramiro Castro-Santamaria Gerald L. Andriole Michael R. Freeman Stephen J. Freedland Source Type: research

The molecular biology of prostate cancer: current understanding and clinical implications
The molecular biology of prostate cancer: current understanding and clinical implicationsThe molecular biology of prostate cancer: current understanding and clinical implications, Published online: 27 December 2017; doi:10.1038/s41391-017-0023-8The molecular biology of prostate cancer: current understanding and clinical implications (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 27, 2017 Category: Urology & Nephrology Authors: Jason Gandhi Adil Afridi Sohrab Vatsia Gargi Joshi Gunjan Joshi Steven A. Kaplan Noel L. Smith Sardar Ali Khan Source Type: research

Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience
Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience, Published online: 27 December 2017; doi:10.1038/s41391-017-0022-9Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 27, 2017 Category: Urology & Nephrology Authors: Daniel Mollengarden Kenneth Goldberg Daniel Wong Claus Roehrborn Source Type: research

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort
Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort, Published online: 22 December 2017; doi:10.1038/s41391-017-0031-8Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 22, 2017 Category: Urology & Nephrology Authors: Ville Kukko Antti Kaipia Kirsi Talala Kimmo Taari Teuvo L. J. Tammela Anssi Auvinen Teemu J. Murtola Source Type: research

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation, Published online: 20 December 2017; doi:10.1038/s41391-017-0014-9The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 20, 2017 Category: Urology & Nephrology Authors: Megan McNamara Christopher Sweeney Emmanuel S. Antonarakis Andrew J. Armstrong Source Type: research

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade, Published online: 20 December 2017; doi:10.1038/s41391-017-0009-6Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 20, 2017 Category: Urology & Nephrology Authors: Rana R. McKay Bruce Montgomery Wanling Xie Zhenwei Zhang Glenn J. Bubley David W. Lin Mark A. Preston Quoc-Dien Trinh Peter Chang Andrew A. Wagner Elahe A. Mostaghel Philip W. Kantoff Peter S. Nelson Adam S. Kibel Mary-Ellen Taplin Source Type: research

Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk
Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk, Published online: 19 December 2017; doi:10.1038/s41391-017-0021-xMaintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 19, 2017 Category: Urology & Nephrology Authors: Yuanjun Ma Nele Brusselaers Source Type: research

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer, Published online: 19 December 2017; doi:10.1038/s41391-017-0024-7Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 19, 2017 Category: Urology & Nephrology Authors: Tobias Nordstr öm Olof Akre Markus Aly Henrik Gr önberg Martin Eklund Source Type: research

20 years—A retrospective of prostate cancer and prostatic diseases
20 years—A retrospective of prostate cancer and prostatic diseases20 years—A retrospective of prostate cancer and prostatic diseases, Published online: 19 December 2017; doi:10.1038/s41391-017-0025-620 years—A retrospective of prostate cancer and prostatic diseases (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 19, 2017 Category: Urology & Nephrology Authors: Stephen J Freedland Source Type: research

Germline BRCA mutation in male carriers—ripe for precision oncology?
Germline BRCA mutation in male carriers—ripe for precision oncology?Germline BRCA mutation in male carriers—ripe for precision oncology?, Published online: 14 December 2017; doi:10.1038/s41391-017-0018-5Germline BRCA mutation in male carriers—ripe for precision oncology? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 14, 2017 Category: Urology & Nephrology Authors: Ricardo Rom ão Nazário Leão Aryeh Joshua Price Robert James Hamilton Source Type: research

Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance
Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance, Published online: 14 December 2017; doi:10.1038/s41391-017-0010-0Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 14, 2017 Category: Urology & Nephrology Authors: David E. Guy Avi Vandersluis Laurence H. Klotz Neil Fleshner Alexander Kiss Chris Parker Vasundara Venkateswaran Source Type: research

Elevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomy
Elevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomyElevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomy, Published online: 11 December 2017; doi:10.1038/s41391-017-0015-8Elevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomy (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2017 Category: Urology & Nephrology Authors: Mehmet Özsoy Marco Moschini Harun Fajkovic Francesco Soria Christian Seitz Tobias Klatte Kilian Gust Alberto Briganti Pierre I. Karakiewicz Morgan Roupret Gero Kramer Shahrokh F. Shariat Source Type: research

Platinum sensitivity in metastatic prostate cancer: does histology matter?
Platinum sensitivity in metastatic prostate cancer: does histology matter?, Published online: 11 December 2017; doi:10.1038/s41391-017-0017-6Platinum sensitivity in metastatic prostate cancer: does histology matter? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2017 Category: Urology & Nephrology Authors: Michael S. Humeniuk Rajan T. Gupta Patrick Healy Megan McNamara Sundhar Ramalingam Michael Harrison Daniel George Tian Zhang Yuan Wu Andrew J. Armstrong Source Type: research

The use of PET/CT in prostate cancer
The use of PET/CT in prostate cancer, Published online: 11 December 2017; doi:10.1038/s41391-017-0007-8The use of PET/CT in prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2017 Category: Urology & Nephrology Authors: Roger Li Gregory C. Ravizzini Michael A. Gorin Tobias Maurer Matthias Eiber Matthew R. Cooperberg Mehrdad Alemozzaffar Matthew K. Tollefson Scott E. Delacroix Brian F. Chapin Source Type: research

Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer
Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer, Published online: 11 December 2017; doi:10.1038/s41391-017-0019-4Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2017 Category: Urology & Nephrology Authors: Brian F. Chapin Jenny N. Nguyen Mary F. Achim Neema Navai Stephen B. Williams Ina N. Prokhorova Xuemei Wang Elsa M. Li Ning Tapia John W. Davis Patricia Troncoso Source Type: research

Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance
Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance, Published online: 07 December 2017; doi:10.1038/s41391-017-0004-yPatient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 7, 2017 Category: Urology & Nephrology Authors: Glenn T. Werneburg Michael Kongnyuy Daniel M. Halpern Jose M. Salcedo Kaitlin E. Kosinski Jonathan A. Haas Jeffrey T. Schiff Anthony T. Corcoran Aaron E. Katz Source Type: research

Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort
Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort, Published online: 06 December 2017; doi:10.1038/s41391-017-0002-0Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 6, 2017 Category: Urology & Nephrology Authors: Bo Tang Cheng-Tao Han Xiao-Lin Lu Fang-Ning Wan Cui-Zhu Zhang Yao Zhu Ding-Wei Ye Source Type: research

Prostate cancer diagnosis and characterization with mass spectrometry imaging
Prostate cancer diagnosis and characterization with mass spectrometry imaging, Published online: 05 December 2017; doi:10.1038/s41391-017-0011-zProstate cancer diagnosis and characterization with mass spectrometry imaging (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 5, 2017 Category: Urology & Nephrology Authors: Annika Kurreck Lindsey A. Vandergrift Taylor L. Fuss Piet Habbel Nathalie Y. R. Agar Leo L. Cheng Source Type: research

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model, Published online: 04 December 2017; doi:10.1038/s41391-017-0013-xCombining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 4, 2017 Category: Urology & Nephrology Authors: Ying-Chun Shen Ali Ghasemzadeh Christina M. Kochel Thomas R. Nirschl Brian J. Francica Zoila A. Lopez-Bujanda Maria A. Carrera Haro Ada Tam Robert A. Anders Mark J. Selby Alan J. Korman Charles G. Drake Source Type: research